Table 1. Clinical and disease characteristics.
| Characteristic | Primary cohort | Recurrent/metastatic cohort (n = 49) |
|---|---|---|
| (n = 90) | ||
| Age at diagnosis–median (range), y | 52 (32–91) | 58 (30–83) |
| Race/ethnicity–no. (%) | ||
| White | 58 (64) | 33 (67) |
| Asian | 4 (4) | 2 (4) |
| Black | 14 (16) | 7 (14) |
| Hispanic | 11 (12) | 4 (8) |
| Other | 3 (3) | 3 (6) |
| Sex–no. (%) | ||
| Female | 86 (96) | 49 (100) |
| Male | 4 (4) | |
| Menopausal status at diagnosis–no. (%) | ||
| Postmenopausal | 61 (71) | 28 (58) |
| Premenopausal | 25 (29) | 20 (42) |
| Unknown | 4 | 1 |
| Histology/cytology–no. (%) | ||
| Invasive ductal carcinoma | 82 (91) | 42 (86) |
| Invasive lobular carcinoma | 2 (2) | 2 (4) |
| Invasive mammary carcinoma | 3 (3) | 2 (4) |
| Metastatic carcinoma | 2 (2) | 3 (6) |
| Poorly differentiated carcinoma | 1 (1) | |
| Stage–no. (%) | ||
| I | 31 (35) | — |
| II | 35 (39) | — |
| III | 23 (26) | — |
| IV de novo | — | 14 (29) |
| Distant recurrence | — | 32 (65) |
| Locoregional recurrence | — | 3 (6) |
| Unknown | 1 | 0 |
| Tumor grade–no. (%) | ||
| 1 | 3 (3) | 0 |
| 2 | 36 (40) | 13 (81) |
| 3 | 50 (56) | 3 (19) |
| Unknown | 1 | 33 |
| Estrogen receptor status–no. (%) | ||
| Positive | 76 (84) | 41 (84) |
| Negative | 14 (16) | 8 (16) |
| Progesterone receptor status–no. (%) | ||
| Positive | 63 (71) | 22 (45) |
| Negative | 26 (29) | 27 (55) |
| Unknown | 1 | |
| FISH ratio–median (range) | 1.3 (1–2) | 1.2 (1–2) |
| HER2 copy number–median (range) | 4.4 (4–6) | 4.43 (4–6) |
| Ki-67 –median (range), % | 25 (2–95) | 22.5 (3–95) |
FISH: fluorescence in situ hybridization. HER2: human epidermal growth factor receptor 2.